68Ga-Nb1159 (Novamab Biopharmaceuticals)

68Ga-Nb1159（洛启生物）

Report date: 2025/11/05 17:48:36

Base Information

Drug Name68Ga-Nb1159 (Novamab Biopharmaceuticals)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Diagnostic agent (In vivo)Radiation-emitting products > Nuclides > Gallium > 68Ga +[6]

Mechanisms of ActionAnti-Coronavirus spike glycoprotein

TargetsProgrammed death-ligand 1Coronavirus spike glycoprotein

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Diagnostic agents

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShanghai Novamab Biopharmaceuticals Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Novamab Biopharmaceuticals Co Ltd

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)Diagnostic agents

Inactive IndicationsN/A

Other Information

ATC CodeN/A